Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma
Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ®, announced today that the FDA has approved an Investigational Device Exemption ...